Compounds > spironolactone
Page last updated: 2024-08-17

spironolactone and abiraterone acetate

spironolactone has been researched along with abiraterone acetate in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Flynn, T; Guancial, EA; Kilari, D; Kilari, M1
Agarwal, N; Alex, A; Bailey, E; Batten, J; Boucher, K; Gaston, D; Gill, D; Gupta, S; Hahn, A; Stenehjem, D1
Beysens, M; Buelens, S; De Bleser, E; Dhondt, B; Lumen, N; Ost, P; Van Besien, J1
Collado-Borrell, R; Escudero-Vilaplana, V; Herranz, A; López-López, C; Revuelta-Herrero, JL; Ruiz-Briones, P; Sanjurjo, M; Somoza-Fernández, B; Vicente-Valor, J; Villanueva-Bueno, C1

Other Studies

4 other study(ies) available for spironolactone and abiraterone acetate

ArticleYear
Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:1

    Topics: Abiraterone Acetate; Benzamides; Drug Antagonism; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Spironolactone; Treatment Outcome

2017
Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:4

    Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Eplerenone; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spironolactone; Survival Analysis; Treatment Outcome

2017
Abiraterone and spironolactone in prostate cancer: a combination to avoid.
    Acta clinica Belgica, 2019, Volume: 74, Issue:6

    Topics: Abiraterone Acetate; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Contraindications, Drug; Disease Progression; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Mineralocorticoid Receptor Antagonists; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Spironolactone; Treatment Outcome; Withholding Treatment

2019
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:5

    Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Spironolactone; Treatment Outcome

2022